Dr. Scott brings more than 20 years of experience in drug discovery research and development to his role as vice president of research at Leading BioSciences. His expertise, which includes leading cross-functional drug discovery project teams, spans all stages of drug discovery including identification and validation of suitable targets, management of low-, medium- and high-throughput screening campaigns, and advancement of hits and leads through preclinical development to IND submission. Prior to joining Leading Bioscience, Dr. Scott was vice president of biology at Dart Neuroscience LLC, where he played a critical role in the establishment of the company’s novel drug discovery platform, as well as identifying compounds and supporting their advancement through preclinical development and into human clinical trials. Before his tenure with Dart Neuroscience, Dr. Scott served as director of discovery systems at Helicon Therapeutics Inc., during which time he was responsible for target identification, assay development and screening for targets relevant to cognitive activity.
He received his bachelor of science in biochemistry from the University of Stirling, Scotland, and his Ph.D. in developmental neuroscience from Columbia University. His postdoctoral training in neuroscience took place at The Rockefeller University.